Standard Biotools Inc
$ 0.80
-0.01%
07 Aug - close price
- Market Cap 314,102,000 USD
- Current Price $ 0.80
- High / Low $ 0.82 / 0.78
- Stock P/E N/A
- Book Value 1.44
- EPS -0.13
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.11 %
- 52 Week High 1.72
- 52 Week Low 0.70
About
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.
Analyst Target Price
$1.55
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-05-08 | 2024-02-28 | 2023-11-07 |
| Reported EPS | -0.05 | -0.02 | 0.0672 | -0.04 | -0.04 | -0.05 | -0.0494 | -0.03 | -0.08 | -0.24 | -0.25 | -0.14 |
| Estimated EPS | -0.03 | -0.02 | -0.0533 | -0.02 | -0.04 | -0.04 | -0.03 | -0.07 | -0.07 | -0.1 | -0.13 | -0.12 |
| Surprise | -0.02 | 0 | 0.1205 | -0.02 | 0 | -0.01 | -0.0194 | 0.04 | -0.01 | -0.14 | -0.12 | -0.02 |
| Surprise Percentage | -66.6667% | 0% | 226.0788% | -100% | 0% | -25% | -64.6667% | 57.1429% | -14.2857% | -140% | -92.3077% | -16.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.08 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LAB
2026-08-06 18:10:47
This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance metrics. The article also includes comparisons with similar medical device companies and recent news regarding analyst actions.
2026-08-06 18:10:47
Standard BioTools Inc. announced its financial results for the second quarter of 2026, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, anticipated to close before year-end 2026, and has withdrawn its full-year 2026 revenue outlook due to this pending merger. The results also highlighted improved gross margins driven by productivity enhancements and cost discipline.
2026-08-05 21:10:47
Standard BioTools (NASDAQ: LAB) reported a revenue decline of 7.6% year-over-year in Q2 2026, reaching $20.1 million, and a widened diluted loss per share from continuing operations. Despite a GAAP net loss increase due to transaction expenses, significant cost reductions and higher gross margins substantially narrowed the adjusted EBITDA loss. The company's revenue contraction affected all categories, and it withdrew its full-year 2026 outlook due to a pending merger with Treeline Biosciences.
2026-08-05 17:43:19
Standard BioTools Inc. (NASDAQ: LAB) reported Q2 2026 revenue of $20.1 million, a 7.6% decrease year-over-year, alongside a narrowing adjusted EBITDA loss to $2.5 million from $16.1 million in Q2 2025. The company is actively moving forward with its merger with Treeline Biosciences and has withdrawn its full-year 2026 revenue outlook due to this pending transaction. Strong liquidity is noted with cash and investments totaling $541.1 million, significantly up from the prior year.
2026-08-05 16:05:00
Standard BioTools Inc. announced its Q2 2026 financial results, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, including a planned divestiture of its Mass Cytometry business and Illumina's early buyout of contingent payments, aiming for a close by year-end 2026 to maximize shareholder value. Due to the pending merger, Standard BioTools has withdrawn its full-year 2026 revenue outlook.
2026-08-04 21:40:14
Standard BioTools (LAB) CEO Michael Egholm had 362,625 shares of common stock withheld on August 3, 2026, to cover tax obligations arising from the vesting of restricted stock units granted on August 1, 2025. The shares were valued at $0.868 each for this tax-withholding disposition, which is not an open-market sale. After this transaction, Egholm directly owns 6,235,331 common shares of Standard BioTools.
